Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
Member
Oklahoma Medical Research FoundationFounded in 1946, this independent nonprofit biomedical research institute conducts basic, translational, and clinical research in critical areas such as heart disease, cancer, autoimmune, and neurodegenerative diseases. Its mission focuses on understanding biological mechanisms and advancing diagnostics and therapeutics. Activities include conducting clinical trials, managing a patent portfolio, commercializing biotechnologies, and supporting the biotech community. Research efforts are funded by grants and philanthropy, and the institute hosts advanced facilities, interdisciplinary research teams, and collaborations with academia and industry.
Founded in 1946, this independent nonprofit biomedical research institute conducts basic, translational, and clinical research in critical areas such as heart disease, cancer, autoimmune, and neurodegenerative diseases. Its mission focuses on understanding biological mechanisms and advancing diagnostics and therapeutics. Activities include conducting clinical trials, managing a patent portfolio, commercializing biotechnologies, and supporting the biotech community. Research efforts are funded by grants and philanthropy, and the institute hosts advanced facilities, interdisciplinary research teams, and collaborations with academia and industry.
Publication Number
US-10398659-B2
Publication Date
2019-09-03
Expiration Date
Abstract
The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.
Core Innovation
2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) is described as a therapeutic agent to treat, prevent, or inhibit recurrence of gliomas, including anaplastic gliomas, astrocytoma, oligodendroglioma, and glioblastoma multiforme. 2,4-ds-PBN is disclosed for administration via enteral routes including dietary supplementation, oral pill or liquid, and via parenteral routes including intravenous administration, and for use in combination with standard therapies such as PCV, DFMO, BCNU/CCNU, radiation, and surgery.
The patent addresses the need for efficacious anti-glioma therapies by inhibiting inducible nitric oxide synthase (iNOS) expression in the brain and by reducing angiogenesis and promoting tumor cell apoptosis. In vivo and cellular data are reported indicating marked tumor volume decrease and increased survival in a rat C6 glioma model and cellular changes including reduced iNOS and VEGF and increased apoptosis; specific experimental parameters are [procedural detail omitted for safety].
Claims Coverage
The claims include one independent claim directed to a method that inhibits inducible nitric oxide synthase (iNOS) protein expression in the brain by administration of 2,4-ds-PBN, yielding one main inventive feature.
Inhibiting inducible nitric oxide synthase protein expression in brain
Administering 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) to a mammalian subject in an amount sufficient to inhibit iNOS protein expression in the brain.
The independent claim is focused on a single inventive feature: use of 2,4-ds-PBN to inhibit brain iNOS protein expression in a mammalian subject by administering an amount sufficient to achieve that inhibition.
Stated Advantages
Therapeutic efficacy against gliomas, stated as treatment, prevention, or inhibition of recurrence.
Unexpected therapeutic potency relative to the parent nitrone PBN, as described in the specification.
Lower toxicity relative to parent PBN, as noted in the specification.
Compatibility with enteral dietary supplementation and with combination use alongside standard glioma therapies.
Reported in vivo efficacy including substantial tumor reduction and increased survival in a rat C6 glioma model (specific experimental parameters are [procedural detail omitted for safety]).
Documented Applications
Treatment, prevention, and inhibition of recurrence of gliomas, including anaplastic gliomas, astrocytoma, oligodendroglioma, and glioblastoma multiforme.
Enteral delivery as dietary supplementation of a food component, including administration as an oral pill or liquid.
Parenteral administration including intravenous or intraarterial delivery.
Adjunctive use in combination with standard therapies for glioma including PCV, DFMO, BCNU/CCNU, radiation therapy, and surgery.
Prophylactic or preventive administration to subjects at elevated risk, including subjects with familial cancer history or exposure to carcinogenic environments such as N-nitroso compounds or X-irradiation.
Interested in licensing this patent?